Christy W. LaFlamme

Christy W. LaFlamme

Auto-generated profile, based on publicly available information

Christy W. LaFlamme

Center for Pediatric Neurological Disease Research, St. Jude Children’s Research Hospital, Memphis, USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2021 in Biological Psychiatry
Verified
Journal Article
Closed access
JLJenna A. Levy
Jenna A. Levy
CLChristy W. LaFlamme
Christy W. LaFlamme
GTGeorge Tsaprailis
George Tsaprailis
GCGogce Crynen
Gogce Crynen
DPDamon T. Page
Damon T. Page

6 August 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
CLChristy W. LaFlamme
Christy W. LaFlamme
CRCassandra Rastin
Cassandra Rastin
SSSoham Sengupta
Soham Sengupta
HPHelen E. Pennington
Helen E. Pennington
SRSophie J. Russ-Hall
Sophie J. Russ-Hall
HMHeather C. Mefford
Heather C. Mefford
Sequence-based genetic testing identifies causative variants in ~ 50% of individuals with developmental and epileptic encephalopathies (DEEs). Aberrant changes in DNA methylation are implicated in various neurodevelopmental disorders but remain unstudied in DEEs. We interrogate the diagnostic utility of genome-wide DNA methylation array analysis on peripheral blood samples from 582 individuals with genetically unsolved DEEs. We identify rare differentially methylated regions (DMRs) and explanatory episignatures to uncover causative and candidate genetic etiologies in 12 individuals. Using long-read sequencing, we identify DNA variants underlying rare DMRs, including one balanced translocation, three CG-rich repeat expansions, and four copy number variants. We also identify pathogenic variants associated with episignatures. Finally, we refine the CHD2 episignature using an 850 K methylation array and bisulfite sequencing to investigate potential insights into CHD2 pathophysiology. Our study demonstrates the diagnostic yield of genome-wide DNA methylation analysis to identify causal and candidate variants as 2% (12/582) for unsolved DEE cases.

7 May 2025 in Science Translational Medicine
Verified
Journal Article
Closed access
HCHelen Chen
Helen Chen
CLChristy W. LaFlamme
Christy W. LaFlamme
YWYong-Dong Wang
Yong-Dong Wang
ABAidan W. Blan
Aidan W. Blan
NKNikki Koehler
Nikki Koehler
HMHeather C. Mefford
Heather C. Mefford
UBA5 encodes for the E1 enzyme of the UFMylation cascade, which plays an essential role in endoplasmic reticulum (ER) homeostasis. The clinical phenotypes of UBA5 -associated encephalopathy include developmental delays, epilepsy, and intellectual disability. To date, there is no humanized neuronal model to study the cellular and molecular consequences of UBA5 pathogenic variants. We developed and characterized patient-derived cortical organoid cultures from two patients with compound heterozygous variants in UBA5 . Both shared the same missense variant, which encodes a hypomorphic allele (p.A371T), along with a nonsense variant (p.G267* or p.A123fs*4). Single-cell RNA sequencing of 100-day organoids identified defects in GABAergic interneuron development. We demonstrated aberrant neuronal firing and reduction in size of patient-derived organoids. Mechanistically, we showed that ER homeostasis is perturbed along with an exacerbated unfolded protein response pathway in engineered U87-MG cells and patient-derived organoids expressing UBA5 pathogenic variants. We also assessed two potential therapeutic modalities that augmented UBA5 protein abundance to rescue aberrant molecular and cellular phenotypes. We assessed SINEUP, a long noncoding RNA that augments translation efficiency, and CRISPRa, a modified CRISPR-Cas9 approach to augment transcription efficiency to increase UBA5 protein production. Our study provides a humanized model that allows further investigations of UBA5 variants in the brain and highlights promising approaches to alleviate cellular aberrations for this rare, developmental disorder.

30 March 2026 in Nature Genetics
Verified
Journal Article
Open access
PDF file
ELElsa Leitão
Elsa Leitão
ASAmandine Santini
Amandine Santini
BCBenjamin Cogne
Benjamin Cogne
MEMiriam Essid
Miriam Essid
MAMaria Athanasiadou
Maria Athanasiadou
CNCaroline Nava
Caroline Nava
Small nuclear RNAs (snRNAs) are essential components of the spliceosome. De novo variants in snRNA genes RNU4-2 (ReNU syndrome), RNU5B-1 and RNU2-2 have been linked to dominant neurodevelopmental disorders (NDDs), revealing a large unexpected contribution of noncoding RNA genes to genetic diseases. Here, through international collaborations, we analyze systematically 200 potentially functional snRNA genes in a French cohort of 34,329 people with rare disorders. We report RNU2-2 variants in 141 individuals, including 35 with recurrent dominant pathogenic variants and 91 affected members from 73 families with biallelic variants. Recessive RNU2-2 NDD is at least twice as frequent as the dominant form and often involves a de novo variant in trans with an inherited allele, consistent with the high mutability of snRNA genes. Dominant and recessive RNU2-2 NDDs share overlapping clinical features, with frequent epilepsy. Blood transcriptomics and DNA methylation analyses revealed subtle, variant-specific effects on splicing and episignatures. Our results support a gradient-of-impact model bridging dominant and recessive inheritance, and establish RNU2-2 variants as a principal contributor to NDDs, nearly as prevalent as ReNU syndrome.

19 November 2025 in Annals of Neurology
Verified
Journal Article
Closed access
ACAnnie T.G. Chiu
Annie T.G. Chiu
MBMark F. Bennett
Mark F. Bennett
HTHarshini Thiyagarajah
Harshini Thiyagarajah
ASAmy L. Schneider
Amy L. Schneider
SMSian M.W. Macdonald
Sian M.W. Macdonald
ISIngrid E. Scheffer
Ingrid E. Scheffer

9 August 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
BGBida Gu
Bida Gu
DPDandan Peng
Dandan Peng
CLChristy W. LaFlamme
Christy W. LaFlamme
MBMark F. Bennett
Mark F. Bennett
MBMelanie Bahlo
Melanie Bahlo
MCMark J.P. Chaisson
Mark J.P. Chaisson
Tandem repeats (TRs) are highly mutable genomic elements composed of repeated motifs that drive genetic diversity and contribute to disease. Due to limited resolution at population scale, their mutation dynamics are incompletely understood. Here, we present TRCompDB, a reference database constructed on 832 human genomes that annotates the compositional diversity and population structure for 4.4 million TR loci. Leveraging SNP-based genealogical trees, we estimated locus-specific mutation rates for 4,037,274 TRs, revealing mutation rates ranging from 10 −10 to 10 −3 on TRCompDB loci. In addition to TR length and coding potential, mutation rate was influenced by recombination and the wider duplication context. Moreover, a subset of AT-rich pentanucleotide repeats including loci linked to Familial Myoclonic Adult Epilepsy and spinocerebellar ataxia showed extreme mutation rates. Beyond single-motif changes, 29,964 loci exhibited higher-order duplication patterns that increased allelic complexity, among which 3,351 VNTRs showed evolutionary recurrence. These results establish TRCompDB as a resource for studying global patterns of tandem repeat evolution and their contribution to human disease.